## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.0% below STRENGTH zone (3.0-6.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. 17,830 Shares in Abbott Laboratories $ABT Bought by B. Riley Wealth Advisors Inc.**
- Source: MarketBeat | 20251215T082440 | Bullish | Relevance: 100%
- B. Riley Wealth Advisors Inc. acquired 17,830 shares of Abbott Laboratories (NYSE:ABT) in the second quarter, valued at approximately $2.43 million, increasing institutional ownership to about 75.18%. Abbott reported strong Q3 earnings, meeting analyst estimates, and increased its quarterly dividend while maintaining a "Moderate Buy" consensus rating from analysts.

**2. Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025**
- Source: ts2.tech | 20251215T001729 | Neutral | Relevance: 100%
- Abbott Laboratories (ABT) faces a busy Monday with several key headlines, including a dividend hike, regulatory attention on FreeStyle Libre sensors, and a major acquisition of Exact Sciences. Investors will also be tracking baby formula litigation and the expansion of Abbott's Lingo product. These factors will influence ABT's stock performance as the market opens, against a backdrop of generally positive analyst sentiment but near-term uncertainties.

**3. Westwood Holdings Group Inc. Reduces Stock Holdings in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251214T142452 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. significantly reduced its stake in Abbott Laboratories, selling 115,293 shares in Q2, though ABT remains its 11th largest holding. Despite this, other institutional investors like American Century Companies Inc. increased their positions, with overall institutional ownership at approximately 75.18%. Abbott Laboratories recently met EPS expectations but slightly missed revenue forecasts, and analysts maintain a "Moderate Buy" rating with an average target price of $147.

**4. Bernstein Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $150**
- Source: 富途牛牛 | 20251214T010822 | Bullish | Relevance: 100%
- Bernstein analyst Lee Hambright has reiterated a Buy rating for Abbott Laboratories (ABT.US) and increased the target price from $145 to $150. According to TipRanks, the analyst has a 61.2% success rate and an average return of 6.9% over the past year. This report provides an analysis of the analyst's performance metrics and includes disclaimers regarding investment advice.

**5. Products and Solutions | Life-Changing Health Tech | Abbott U.S**
- Source: Abbott | 20251212T170816 | Bullish | Relevance: 100%
- Abbott offers a wide range of life-changing health technologies across various fields including diabetes, nutrition, diagnostics, cardiovascular health, pain management, biowearables, and medicines. The company highlights products like the FreeStyle Libre systems for continuous glucose monitoring, nutrition products such as Ensure and Pedialyte, and advanced cardiovascular solutions. Detailed safety information, indications, contraindications, warnings, precautions, and potential adverse events are provided for medical devices like the AVEIR DR Leadless Pacemaker System, Liberta RC DBS System, SCS Systems, and TriClip G4 System.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($0.12M) |
| Sells | 1 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +6.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.1x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $218.4B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.1 |
| Current P/E | 24.3 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.4% to 2.0% (+6.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.0pp (needs >3.0% for momentum thesis). MRS_5 at 3.5% confirms short-term momentum alignment. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 48. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.02% (CS: 53) | Neutral |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 0.993x | Below |
| vs SMA50 | 0.983x | Below |
| vs SMA200 | 0.961x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.46
- **Stop Loss:** $120.52 (3.9% risk)
- **Target:** $130.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 202
- **Position Value:** $25,342.92
- **Portfolio %:** 25.34%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*